12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CLS 1002: Phase I/II data

An open-label, Mexican Phase I/II trial in 4 patients with wet AMD showed that CLS 1002 delivered via Clearside's ocular microinjection platform was well tolerated with no adverse events reported. The platform, which delivers drugs to the choroid and retina...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >